Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Valerie Nelson
Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2−negative Endocrine-Refractory Metastatic Breast Cancer
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Related publications
Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
Frontiers in Oncology
Cancer Research
Oncology
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Geburtshilfe und Frauenheilkunde
Gynecology
Midwifery
Maternity
Obstetrics
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients
Oncologist
Cancer Research
Medicine
Oncology
Overall Survival and Progression-Free Survival With Endocrine Therapy for Hormone Receptor-Positive, HER2-negative Advanced Breast Cancer: Review
Therapeutic Advances in Medical Oncology
Oncology
Androgen Receptor-Positive, Triple-Negative Breast Cancer
Cancer
Cancer Research
Oncology
CDK4/6 Inhibitors for Hormone Receptor-Positive HER2-negative Metastatic Breast Cancer: Does One Size Fit All?
Future Medicinal Chemistry
Drug Discovery
Molecular Medicine
Pharmacology
A Multigene Predictor of Metastatic Outcome in Early Stage Hormone Receptor-Negative and Triple-Negative Breast Cancer
Breast Cancer Research
Cancer Research
Oncology
Alcohol, Smoking, and Risk of Her2-Overexpressing and Triple-Negative Breast Cancer Relative to Estrogen Receptor-Positive Breast Cancer
International Journal of Cancer
Cancer Research
Oncology
